{"doi":"10.1055/s-011-50428","title":"Untitled","abstract":"Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer deaths worldwide and the fastest-rising cause of cancer mortality in the United States, largely driven by an aging hepatitis C virus (HCV)-infected population and a growing number of persons with nonalcoholic steatohepatitis. 1 Cirrhosis is the strongest risk factor for HCC, with over 90% of HCC arising in the background of cirrhosis and HCC being the leading cause of death in patients with compensated cirrhosis. arly detection of HCC significantly impacts overall survival with curative treatment options available only if patients are diagnosed at an early stage. 3,4 However, prognosis and management decisions for HCC are more complex than many other solid tumors, given it arises in the setting of chronic liver disease, which leads to an inherent competing risk of mortality and inevitably impacts therapeutic decisions. Accordingly, the Barcelona Clinic Liver Cancer (BCLC) system-the most widely accepted HCC staging system worldwide-includes degree of liver dysfunction and Eastern Cooperative Oncology Group (ECOG) performance status in addition to tumor burden. he BCLC system has also been linked to a treatment algorithm and subsequent prognosis. Patients detected at an early stage (BCLC 0-A) can achieve 5-year survival exceeding 70% with curative treatments, including surgical resection, liver transplantation, and local ablation. In contrast, patients with intermediate or advanced stages (BCLC B or C) are amenable to palliative therapies such as transarterial chemoembolization (TACE), transarterial radioembolization (TARE), or systemic therapy and have a median survival of 1 to 3 years. However, there is marked heterogeneity within each BCLC stage and a single treatment strategy is not optimal for all patients, particularly after accounting for other factors such as age, comorbidities, tumor biology, patient preferences, and center expertise. These considerations highlight the need for a multidisciplinary approach Keywords liver cancer treatment multidisciplinary guideline-concordant care hepatocellular carcinoma","journal":"Seminars in Liver Disease","year":2021,"id":229185,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.952,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[],"reference_count":40,"raw_metadata":null,"created_at":"2026-07-18T23:54:57.922333Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}